


[EBMT](#)  
[Annual report](#)  
[2024](#)



[ScienceEducationPatient Care & Advocacy](#)  
[Our SocietyOur Mission, Vision & ValuesEBMT Membership 2024Organisational Structure 2024Financial Highlights 2024EBMT Partners](#)

## Breadcrumb

1. [Home](#)

## Entity Print



Annalisa Ruggeri  
CTIWP Chair  
Italy

## Major achievements

The CTIWP is growing in line with the increasing application of cell therapy in different diseases.

The collaboration with the different working parties and partner society (GoCART, EHA) is ongoing with the aim to harmonise the practice and the workload in the cell

therapy field. Communication and regular meetings with the stakeholders are in place to ensure the high quality of researches.

The research activity of the CTIWP is wide and focus on different factors associated with transplant outcomes (immunogenetics and conditioning regimens), as well with CAR T cell therapy. In particular, the fertility after CAR T is being investigated, and the use of CAR T in patients with autoimmune disease, as primary or concomitant disease. This study will open new insight in the application of CAR T in non-malignant diseases.

Another important ongoing evaluation is the outcomes of CAR T cell therapies in older patients who are frail, focusing on toxicities and long term results.



ADWP and CTIWP Educational Meeting Joint Educational Meeting of the ADWP and CTIWP "Immunology and Cellular Therapies in Autoimmune Diseases" - Milan, Italy - 10-12 October 2024

# Principal research studies

[HLA Mismatch Frequencies in Unrelated Hematopoietic Cell Transplantation](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[Allogeneic - Unrelated](#)

[Principal investigator](#)

[Esteban Arrieta Bolaños](#)

[CAR-T in elderly patients](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Non-Hodgkin's Lymphoma \(NHL\)](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Vanderson Rocha](#)

[Impact of fludarabine dose modification in conditioning regimen for CAR T-cell therapy](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Non-Hodgkin's Lymphoma \(NHL\)](#)

[Acute Lymphatic Leukaemia \(ALL\)](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Guillaume Dachy](#)

[Autoimmune and autoinflammatory complications after CAR-T cell therapy - a joint study on behalf of the EBMT - ADWP, CTIWP and TCWP](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Lymphatic Leukaemia \(ALL\)](#)

[Multiple Myeloma \(MM\) or other Plasma Cell Disorder \(PCD\)](#)

[Non-Hodgkin's Lymphoma \(NHL\)](#)

[Group](#)

[GoCART Coalition](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Complications Working Party \(CWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Matteo Doglio](#)

[Survey on fertility procedures and outcomes for patients treated with CAR-T cell therapy](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Giorgio Orofino](#)

## **Key publications**

[2024](#)

[Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party \(CTIWP\) of the EBMT](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[1st listed author](#)

[Piera Angelillo](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2024](#)

[Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[1st listed author](#)

[Esteban Arrieta-Bolaños](#)

[Journal](#)

[Blood.](#)

[2024](#)

[Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[1st listed author](#)

[Esteban Arrieta-Bolaños](#)

[Journal](#)

[J Clin Oncol.](#)

[2024](#)

[Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Practice Harmonisation and Guidelines Committee](#)

[1st listed author](#)

[Simona Pagliuca](#)

[Journal](#)

[Lancet Haematol.](#)

[2024](#)

[Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy \(ISCT\) and the European Society for Blood and Marrow Transplantation \(EBMT\)](#)

[1st listed author](#)

[Fermin Sanchez-Guijo](#)


[Journal](#)

[Cytotherapy.](#)

[See the full list of the CTIWP 2024 publications](#)



## Indicators



**2022 2023 2024**

<b>Oral presentations</b>	<b>2</b>	<b>7</b>	<b>7</b>
<b>Poster presentations</b>	<b>4</b>	<b>4</b>	<b>7</b>
<b>Educational events</b>	<b>7</b>	<b>7</b>	<b>6</b>



[Event](#)

## [\*\*Immunology and Cellular Therapies in Autoimmune Diseases\*\*](#)

[Oct 10, 2024 - Oct 12, 2024 / Milan, Italy](#)

[Discover more](#)




[Event](#)

## **[9th International Transplant and Cellular Therapy Course](#)**



[Event](#)

## **50th Annual Meeting of the EBMT**



[Kingdom](#)

[Event](#)

### **[EBMT-EHA 6th European CAR T-cell Meeting](#)**

[Feb 15, 2024 - Mar 17, 2024 / Valencia, Spain](#)

[Discover more](#)

[VISIT THE CTIWP WEBPAGE](#)